Genetic ablation and pharmaceutical inhibition of ACAT1/SOAT1 have been reported to reduce CE, ameliorate AD-associated pathological hallmarks, and attenuate neuroinflammation via modulating toll-like receptor 4 (TLR4) [23,24,25,26,27,28,29,30]. This evidence concerns the gene ACAT1 and Alzheimer disease.